{"relationship_key":"HGNC:10861:ASSOCIATED_WITH:C0009324","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":153,"text_span":"The mRNA expression levels of ST3Gal1 in the mucosal tissue of individuals diagnosed with UC were significantly higher than those in healthy colon mucosa","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:INCREASES_RISK:canon-38261cafa86a","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":151,"text_span":"ST3Gal1 knockdown in the IEC monolayer increased the barrier function, whereas its overexpression resulted in intestinal barrier function deterioration","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:INCREASES_RISK:canon-38261cafa86a","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":144,"text_span":"The TEER levels in the ST3Gal1-sh3/IEC group were significantly higher than those in the IEC and sh-Ctr/IEC groups after stimulation with 2% DSS","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:7512","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":186,"text_span":"ST3Gal1 knockdown in IECs significantly increased the mRNA levels of MUC2, TFF3 and CDX2, but significantly decreased the mRNA levels of STAT3 in the inflamed stable triple culture model","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:11757","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":186,"text_span":"ST3Gal1 knockdown in IECs significantly increased the mRNA levels of MUC2, TFF3 and CDX2, but significantly decreased the mRNA levels of STAT3 in the inflamed stable triple culture model","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:1806","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":186,"text_span":"ST3Gal1 knockdown in IECs significantly increased the mRNA levels of MUC2, TFF3 and CDX2, but significantly decreased the mRNA levels of STAT3 in the inflamed stable triple culture model","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:11364","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":186,"text_span":"ST3Gal1 knockdown in IECs significantly increased the mRNA levels of MUC2, TFF3 and CDX2, but significantly decreased the mRNA levels of STAT3 in the inflamed stable triple culture model","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:5992","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":134,"text_span":"knockdown of ST3Gal1 significantly reduced the mRNA expression levels of IL-1β, IL-6 and IL-8 in the inflamed intestinal IEC monolayer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:5992","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":150,"text_span":"the overexpression of ST3Gal1 in ST3Gal1-OE/IEC cells significantly elevated the mRNA levels of IL-1β, IL-6 and IL-8 within the inflamed IEC monolayer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:5992","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":197,"text_span":"correlation analyses revealed positive correlations between ST3Gal1 mRNA expression and the expression levels of the cytokines IL-1β, IL-6, IL-8 and STAT3 in the lesional mucosa of patients with UC","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6018","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":134,"text_span":"knockdown of ST3Gal1 significantly reduced the mRNA expression levels of IL-1β, IL-6 and IL-8 in the inflamed intestinal IEC monolayer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6018","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":150,"text_span":"the overexpression of ST3Gal1 in ST3Gal1-OE/IEC cells significantly elevated the mRNA levels of IL-1β, IL-6 and IL-8 within the inflamed IEC monolayer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6018","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":197,"text_span":"correlation analyses revealed positive correlations between ST3Gal1 mRNA expression and the expression levels of the cytokines IL-1β, IL-6, IL-8 and STAT3 in the lesional mucosa of patients with UC","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6025","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":134,"text_span":"knockdown of ST3Gal1 significantly reduced the mRNA expression levels of IL-1β, IL-6 and IL-8 in the inflamed intestinal IEC monolayer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6025","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":150,"text_span":"the overexpression of ST3Gal1 in ST3Gal1-OE/IEC cells significantly elevated the mRNA levels of IL-1β, IL-6 and IL-8 within the inflamed IEC monolayer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6025","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":197,"text_span":"correlation analyses revealed positive correlations between ST3Gal1 mRNA expression and the expression levels of the cytokines IL-1β, IL-6, IL-8 and STAT3 in the lesional mucosa of patients with UC","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:CATALYZES:canon-221f7f6cbeaf","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":151,"text_span":"ST3Gal1 knockdown in the IEC monolayer increased the barrier function, whereas its overexpression resulted in intestinal barrier function deterioration","confidence":0.95,"supports":true}
{"relationship_key":"canon-3b254cef6709:INDUCES:C0009324","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":144,"text_span":"The TEER levels in the ST3Gal1-sh3/IEC group were significantly higher than those in the IEC and sh-Ctr/IEC groups after stimulation with 2% DSS","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:9581:INCREASES_RISK:C0476089","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":141,"text_span":"PTBP1 knockdown significantly suppressed tumor growth in vivo and markedly reduced Ki67 protein levels in the corresponding xenograft tissues","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9581:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":142,"text_span":"PTBP1 knockdown significantly increased ROS levels, reduced intracellular GSH concentrations, and elevated levels of both MDA and ferrous ions","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9581:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":120,"text_span":"PTBP1 knockdown significantly upregulated the expression of ACSL4, while downregulating the expression of GPX4 and HSP27","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9581:ASSOCIATED_WITH:HGNC:11059","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":136,"text_span":"The fold enrichment of SLC7A11 mRNA in anti-PTBP1 immunoprecipitations revealed approximately a four-fold increase in SLC7A11 enrichment","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9581:ASSOCIATED_WITH:HGNC:11059","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":79,"text_span":"The half-life of SLC7A11 mRNA was significantly shortened upon PTBP1 disruption","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11059:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":138,"text_span":"SLC7A11 restoration partially but significantly rescued cell viability and substantially diminished PTBP1 knockdown-induced ROS production","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:4556:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":120,"text_span":"PTBP1 knockdown significantly upregulated the expression of ACSL4, while downregulating the expression of GPX4 and HSP27","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:3571:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":120,"text_span":"PTBP1 knockdown significantly upregulated the expression of ACSL4, while downregulating the expression of GPX4 and HSP27","confidence":0.95,"supports":true}
{"relationship_key":"1797886:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":142,"text_span":"PTBP1 knockdown significantly increased ROS levels, reduced intracellular GSH concentrations, and elevated levels of both MDA and ferrous ions","confidence":0.95,"supports":true}
{"relationship_key":"1797887:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":142,"text_span":"PTBP1 knockdown significantly increased ROS levels, reduced intracellular GSH concentrations, and elevated levels of both MDA and ferrous ions","confidence":0.95,"supports":true}
{"relationship_key":"canon-ebcc3ea63dab:INCREASES_RISK:C0024623","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":131,"text_span":"H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:16848:ASSOCIATED_WITH:C0024623","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":159,"text_span":"YY1 was highly expressed in gastric cancer tissues and cells. Kaplan-Meier survival curves indicated that high YY1 expression correlated with a poor prognosis.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:16848:ACTIVATES:HGNC:6192","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":72,"text_span":"YY1 and JAK2 interaction was validated by chromatin immunoprecipitation.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:6192:ACTIVATES:HGNC:11364","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":131,"text_span":"H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:16848:PROMOTES:canon-dc2593c6b0a9","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":131,"text_span":"H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:16848:PROMOTES:canon-dc2593c6b0a9","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":121,"text_span":"YY1 knockdown or pharmacological inhibition reversed EMT and suppressed gastric cancer cell proliferation and metastasis.","confidence":0.9,"supports":true}
{"relationship_key":"canon-ebcc3ea63dab:UPREGULATES:HGNC:16848","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":131,"text_span":"H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.9,"supports":true}
{"relationship_key":"C0389995:INHIBITS:HGNC:6192","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":121,"text_span":"YY1 knockdown or pharmacological inhibition reversed EMT and suppressed gastric cancer cell proliferation and metastasis.","confidence":0.9,"supports":true}
{"relationship_key":"canon-7996c1367224:ACTIVATES:HGNC:6192","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":121,"text_span":"YY1 knockdown or pharmacological inhibition reversed EMT and suppressed gastric cancer cell proliferation and metastasis.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:9563:INCREASES_RISK:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":223,"text_span":"PSMD14 demonstrates elevated mRNA expression across multiple cancer types compared to normal tissues. In lung adenocarcinoma (LUAD), PSMD14 is upregulated not only at the transcriptional level but also at the protein level.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:INCREASES_RISK:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":313,"text_span":"Kaplan–Meier survival analysis demonstrated that patients with high PSMD14 expression had significantly worse overall survival (OS, p = 0.003), disease-specific survival (DSS, p = 0.001), progression-free interval (PFI, p < 0.001), and disease-free interval (DFI, p < 0.001) compared to those with low expression.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:ASSOCIATED_WITH:HGNC:5012","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":279,"text_span":"Using co-immunoprecipitation (Co-IP) assays, we confirmed a specific interaction between PSMD14 and HMMR. Subsequent knockdown and overexpression of PSMD14 in LUAD cell lines demonstrated that HMMR expression is positively regulated by PSMD14 at both the mRNA and protein levels.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:REGULATES:HGNC:5012","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":279,"text_span":"Using co-immunoprecipitation (Co-IP) assays, we confirmed a specific interaction between PSMD14 and HMMR. Subsequent knockdown and overexpression of PSMD14 in LUAD cell lines demonstrated that HMMR expression is positively regulated by PSMD14 at both the mRNA and protein levels.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:REGULATES:HGNC:5012","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":158,"text_span":"PSMD14 knockdown markedly enhanced HMMR ubiquitination, whereas its overexpression reduced it. PSMD14 primarily cleaved K63-linked ubiquitin chains from HMMR.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:ACTIVATES:HGNC:11766","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":264,"text_span":"PSMD14 knockdown reduced TGF-β, p-Smad2/3 phosphorylation, and CD44 expression, whereas PSMD14 overexpression increased these markers. Similarly, PSMD14 knockdown decreased phosphorylation of mTOR, PI3K, and AKT, while its overexpression enhanced their activation.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:ACTIVATES:HGNC:8975","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":264,"text_span":"PSMD14 knockdown reduced TGF-β, p-Smad2/3 phosphorylation, and CD44 expression, whereas PSMD14 overexpression increased these markers. Similarly, PSMD14 knockdown decreased phosphorylation of mTOR, PI3K, and AKT, while its overexpression enhanced their activation.","confidence":0.95,"supports":true}
{"relationship_key":"canon-3a48175d203c:TREATS:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":181,"text_span":"The PSMD14 inhibitor Capzimin exhibited potent anti-tumor effects in vitro and in vivo, and combination therapy with the TGF-β inhibitor galunisertib demonstrated enhanced efficacy.","confidence":0.95,"supports":true}
{"relationship_key":"1598392:TREATS:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":181,"text_span":"The PSMD14 inhibitor Capzimin exhibited potent anti-tumor effects in vitro and in vivo, and combination therapy with the TGF-β inhibitor galunisertib demonstrated enhanced efficacy.","confidence":0.95,"supports":true}
{"relationship_key":"canon-be07eb86995b:INDICATES:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":380,"text_span":"DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p < 0.001), (ii) significantly reduced CD8+ T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% vs 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003).","confidence":0.95,"supports":true}
{"relationship_key":"1298331:TREATS:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":380,"text_span":"DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p < 0.001), (ii) significantly reduced CD8+ T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% vs 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003).","confidence":0.95,"supports":true}
{"relationship_key":"1298331:TREATS:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":252,"text_span":"In the independent MSK-IMPACT validation cohort (n=152), the DDR-IF score successfully stratified patients, with DDR-IF-high status being associated with significantly improved progression-free survival on PARP-ICB regimens (HR 0.45, 95% CI 0.22-0.91).","confidence":0.9,"supports":true}
{"relationship_key":"canon-151ca0125b35:TREATS:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":380,"text_span":"DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p < 0.001), (ii) significantly reduced CD8+ T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% vs 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003).","confidence":0.95,"supports":true}
{"relationship_key":"canon-151ca0125b35:TREATS:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":252,"text_span":"In the independent MSK-IMPACT validation cohort (n=152), the DDR-IF score successfully stratified patients, with DDR-IF-high status being associated with significantly improved progression-free survival on PARP-ICB regimens (HR 0.45, 95% CI 0.22-0.91).","confidence":0.9,"supports":true}
{"relationship_key":"canon-7ae89029ace8:ASSOCIATED_WITH:canon-be07eb86995b","document_id":"extracted","section":null,"start_offset":0,"end_offset":167,"text_span":"The score, constructed using elastic-net regression, incorporates homologous recombination deficiency (HRD), tumor mutational burden (TMB), and STING pathway activity.","confidence":0.9,"supports":true}
{"relationship_key":"canon-a2900992bc74:ASSOCIATED_WITH:canon-be07eb86995b","document_id":"extracted","section":null,"start_offset":0,"end_offset":167,"text_span":"The score, constructed using elastic-net regression, incorporates homologous recombination deficiency (HRD), tumor mutational burden (TMB), and STING pathway activity.","confidence":0.9,"supports":true}
{"relationship_key":"canon-709d74f449c4:ASSOCIATED_WITH:canon-be07eb86995b","document_id":"extracted","section":null,"start_offset":0,"end_offset":167,"text_span":"The score, constructed using elastic-net regression, incorporates homologous recombination deficiency (HRD), tumor mutational burden (TMB), and STING pathway activity.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:795:ASSOCIATED_WITH:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":202,"text_span":"Recent global epidemiological data (2024) confirm that more than 70% of ES-SCLC cases carry at least one actionable DDR defect, with frequent alterations in genes such as ATM (11.2%) and BRCA1/2 (6.7%).","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:1100:ASSOCIATED_WITH:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":202,"text_span":"Recent global epidemiological data (2024) confirm that more than 70% of ES-SCLC cases carry at least one actionable DDR defect, with frequent alterations in genes such as ATM (11.2%) and BRCA1/2 (6.7%).","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:1101:ASSOCIATED_WITH:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":202,"text_span":"Recent global epidemiological data (2024) confirm that more than 70% of ES-SCLC cases carry at least one actionable DDR defect, with frequent alterations in genes such as ATM (11.2%) and BRCA1/2 (6.7%).","confidence":0.85,"supports":true}
{"relationship_key":"canon-14934aac7185:ASSOCIATED_WITH:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":202,"text_span":"Recent global epidemiological data (2024) confirm that more than 70% of ES-SCLC cases carry at least one actionable DDR defect, with frequent alterations in genes such as ATM (11.2%) and BRCA1/2 (6.7%).","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:1100:INCREASES_RISK:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":133,"text_span":"approximately 5-15% of cases linked to pathogenic variants primarily in BRCA1 or BRCA2. These mutations greatly increase cancer risks","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1100:INCREASES_RISK:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":82,"text_span":"Carriers of BRCA1 mutation may have higher risk of both breast and ovarian cancers","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:1101:INCREASES_RISK:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":133,"text_span":"approximately 5-15% of cases linked to pathogenic variants primarily in BRCA1 or BRCA2. These mutations greatly increase cancer risks","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1101:INCREASES_RISK:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":182,"text_span":"Carriers of pathogenic BRCA2 variants have a lifetime risk of developing breast cancer ranging from 38% to 84%, while the risk of developing ovarian cancer ranges from 16.5% to 27.0%","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1100:INCREASES_RISK:C0029925","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":82,"text_span":"Carriers of BRCA1 mutation may have higher risk of both breast and ovarian cancers","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:1101:INCREASES_RISK:C0029925","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":182,"text_span":"Carriers of pathogenic BRCA2 variants have a lifetime risk of developing breast cancer ranging from 38% to 84%, while the risk of developing ovarian cancer ranges from 16.5% to 27.0%","confidence":0.9,"supports":true}
{"relationship_key":"C0024485:INDICATES:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":140,"text_span":"Annual magnetic resonance imaging (MRI) remains the most sensitive screening tool for early breast cancer detection in high-risk individuals","confidence":0.9,"supports":true}
{"relationship_key":"C0360135:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":118,"text_span":"Selective estrogen receptor modulators (SERMs) and aromatase inhibitors have shown potential as chemopreventive agents","confidence":0.8,"supports":true}
{"relationship_key":"C0593802:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":118,"text_span":"Selective estrogen receptor modulators (SERMs) and aromatase inhibitors have shown potential as chemopreventive agents","confidence":0.8,"supports":true}
{"relationship_key":"C0195471:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":144,"text_span":"Risk-reducing surgeries, such as bilateral salpingo-oophorectomy (BSO) and mastectomy, significantly lower the risk of breast and ovarian cancer","confidence":0.9,"supports":true}
{"relationship_key":"C0195471:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":255,"text_span":"those who underwent risk-reducing BSO had a lower risk of first breast cancer diagnosis compared with those who did not: 7% versus 23% in BRCA2 carriers (HR: 0.36 (95% CI: 0.16 - 0.82)) and 14% versus 20% in BRCA1 carriers (HR: 0.63 (95% CI: 0.41 - 0.96))","confidence":0.9,"supports":true}
{"relationship_key":"C0195471:TREATS:C0029925","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":144,"text_span":"Risk-reducing surgeries, such as bilateral salpingo-oophorectomy (BSO) and mastectomy, significantly lower the risk of breast and ovarian cancer","confidence":0.9,"supports":true}
{"relationship_key":"C0024881:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":144,"text_span":"Risk-reducing surgeries, such as bilateral salpingo-oophorectomy (BSO) and mastectomy, significantly lower the risk of breast and ovarian cancer","confidence":0.9,"supports":true}
{"relationship_key":"C0024881:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":122,"text_span":"prophylactic bilateral mastectomy (PBM) which has been shown to reduce the incidence of breast cancer by approximately 90%","confidence":0.9,"supports":true}
{"relationship_key":"10324:SUBTYPE_OF:C0360135","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":117,"text_span":"The adjusted HRs were 0.38 (95% CI: 0.27 - 0.55) for BRCA1 carriers and 0.33 (95% CI: 0.22 - 0.50) for BRCA2 carriers","confidence":0.9,"supports":true}
{"relationship_key":"69278:SUBTYPE_OF:C0593802","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":138,"text_span":"exemestane use was associated with significant reduction in invasive breast cancers in all study subgroups (HR: 0.35, 95% CI: 0.18 - 0.70)","confidence":0.9,"supports":true}
{"relationship_key":"10324:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":117,"text_span":"The adjusted HRs were 0.38 (95% CI: 0.27 - 0.55) for BRCA1 carriers and 0.33 (95% CI: 0.22 - 0.50) for BRCA2 carriers","confidence":0.9,"supports":true}
{"relationship_key":"69278:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":138,"text_span":"exemestane use was associated with significant reduction in invasive breast cancers in all study subgroups (HR: 0.35, 95% CI: 0.18 - 0.70)","confidence":0.9,"supports":true}
{"relationship_key":"canon-1f4ee4235c43:ASSOCIATED_WITH:HGNC:9581","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"canon-1f4ee4235c43:ASSOCIATED_WITH:HGNC:9581","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":140,"text_span":"HRD-high group exhibited higher mutation frequencies in TP53, RAD51, and SPOP, but fewer mutations in PTEN, ARID1A, PIK3R1, CTNNB1, and CTCF","confidence":0.9,"supports":true}
{"relationship_key":"canon-1f4ee4235c43:ASSOCIATED_WITH:canon-6106ad8550f5","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"canon-7ae89029ace8:INDICATES:canon-48930ec23430","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":162,"text_span":"HRD subtyping independently predicted disease-free survival and showed superior prognostic accuracy (C-index = 0.857) compared to TCGA subtyping (C-index = 0.751)","confidence":0.95,"supports":true}
{"relationship_key":"canon-7ae89029ace8:INDICATES:canon-f4db72f0dd7b","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":107,"text_span":"An SVM model incorporating HRD score and immune features achieved an AUC of 0.733 for recurrence prediction","confidence":0.9,"supports":true}
{"relationship_key":"1797886:TREATS:C0476089","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"canon-da7c09e38e2f:TREATS:C0476089","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"canon-1f4ee4235c43:SUBTYPE_OF:canon-7ae89029ace8","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"canon-1c46bcdf7eba:SUBTYPE_OF:canon-7ae89029ace8","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"canon-7d99d5f676ef:SUBTYPE_OF:canon-7ae89029ace8","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:4556:ASSOCIATED_WITH:HGNC:9581","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":140,"text_span":"HRD-high group exhibited higher mutation frequencies in TP53, RAD51, and SPOP, but fewer mutations in PTEN, ARID1A, PIK3R1, CTNNB1, and CTCF","confidence":0.9,"supports":true}
{"relationship_key":"C0281477:INDICATES:C0006826","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":216,"text_span":"As a critical component of cancer control, cancer screening assumes a pivotal role in early detection, potentially saving lives by identifying cancers in their early stages or preventing their development altogether.","confidence":0.9,"supports":true}
{"relationship_key":"C1531652:INDICATES:C0242379","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":150,"text_span":"Lung cancer has the highest incidence rate in China, and the National Cancer Center recommends low-dose spiral CT screening for high-risk individuals.","confidence":0.9,"supports":true}
{"relationship_key":"C0009378:INDICATES:C1527249","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":150,"text_span":"Lung cancer has the highest incidence rate in China, and the National Cancer Center recommends low-dose spiral CT screening for high-risk individuals.","confidence":0.9,"supports":true}
{"relationship_key":"C0002210:INDICATES:C0023903","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":150,"text_span":"Lung cancer has the highest incidence rate in China, and the National Cancer Center recommends low-dose spiral CT screening for high-risk individuals.","confidence":0.9,"supports":true}
{"relationship_key":"C0024671:INDICATES:C0006142","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":150,"text_span":"Lung cancer has the highest incidence rate in China, and the National Cancer Center recommends low-dose spiral CT screening for high-risk individuals.","confidence":0.9,"supports":true}
{"relationship_key":"C0021344:INDICATES:C0007847","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":150,"text_span":"Lung cancer has the highest incidence rate in China, and the National Cancer Center recommends low-dose spiral CT screening for high-risk individuals.","confidence":0.9,"supports":true}
{"relationship_key":"canon-26d330f77f52:ASSOCIATED_WITH:C0281477","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"canon-26d330f77f52:ASSOCIATED_WITH:C0281477","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":258,"text_span":"Structural equation modeling (SEM) indicated that knowledge directly influenced attitude (β = 0.140, P = 0.003), attitude directly affected practice (β = 0.145, P = 0.002), and knowledge had a substantial and direct impact on practice (β = 0.219, P < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"canon-898c67c8084d:ASSOCIATED_WITH:HGNC:1100","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":168,"text_span":"BRCA1/2 (e.g. 5296del4 in BRCA1 and 6174delT in BRCA2) mutation was considered as the crucial risk factor in breast cancer, and BRCA2 mutations were more common in MBC.","confidence":0.9,"supports":true}
{"relationship_key":"canon-9505ace47936:ASSOCIATED_WITH:HGNC:1101","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":168,"text_span":"BRCA1/2 (e.g. 5296del4 in BRCA1 and 6174delT in BRCA2) mutation was considered as the crucial risk factor in breast cancer, and BRCA2 mutations were more common in MBC.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1100:INCREASES_RISK:C0006142","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":168,"text_span":"BRCA1/2 (e.g. 5296del4 in BRCA1 and 6174delT in BRCA2) mutation was considered as the crucial risk factor in breast cancer, and BRCA2 mutations were more common in MBC.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1101:INCREASES_RISK:C0006142","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":168,"text_span":"BRCA1/2 (e.g. 5296del4 in BRCA1 and 6174delT in BRCA2) mutation was considered as the crucial risk factor in breast cancer, and BRCA2 mutations were more common in MBC.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1101:INCREASES_RISK:C0238033","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":168,"text_span":"BRCA1/2 (e.g. 5296del4 in BRCA1 and 6174delT in BRCA2) mutation was considered as the crucial risk factor in breast cancer, and BRCA2 mutations were more common in MBC.","confidence":0.9,"supports":true}
{"relationship_key":"canon-757746f4f9bd:ASSOCIATED_WITH:C0238033","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"canon-ea7f94e65cba:ASSOCIATED_WITH:C0238033","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"canon-757746f4f9bd:ASSOCIATED_WITH:canon-0e51f8890c84","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":208,"text_span":"Apart from the result that there was a significantly higher proportion of Mongolian patients who used chemotherapy (38.7% vs 25.0%, P=0.020), no significant disparities were observed in the treatment pattern.","confidence":0.95,"supports":true}
{"relationship_key":"canon-ea7f94e65cba:ASSOCIATED_WITH:canon-0e51f8890c84","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":208,"text_span":"Apart from the result that there was a significantly higher proportion of Mongolian patients who used chemotherapy (38.7% vs 25.0%, P=0.020), no significant disparities were observed in the treatment pattern.","confidence":0.95,"supports":true}
{"relationship_key":"C0011847:INCREASES_RISK:C0238033","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"C0028754:INCREASES_RISK:C0238033","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"canon-effb0a169bdf:SUPERIOR_TO:canon-097b6268b348","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-effb0a169bdf:SUPERIOR_TO:canon-097b6268b348","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":185,"text_span":"Among patients with translocation‐related sarcomas, histology‐specific fusion genes were identified in 77.5% using the dual panel, compared to 40.0% with the DNA‐only panel (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"canon-effb0a169bdf:DETECTS:canon-792b872f0f39","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-097b6268b348:DETECTS:canon-792b872f0f39","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-effb0a169bdf:ENABLES:2058257","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":172,"text_span":"Molecular targeted therapy was administered more frequently in the GenMineTOP group (10 of 231 patients, 4.3%) than in the F1CDx group (7 of 464 patients, 1.5%) (p = 0.03).","confidence":0.95,"supports":true}
{"relationship_key":"canon-effb0a169bdf:DETECTS:canon-f1e1e906f98c","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":89,"text_span":"GPVs were detected in 21 patients (5.7%) using the tumor–normal matched GenMineTOP panel.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:3508:FUSES_WITH:HGNC:3749","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11541:FUSES_WITH:HGNC:11335","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:2197:FUSES_WITH:HGNC:8800","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":172,"text_span":"Molecular targeted therapy was administered more frequently in the GenMineTOP group (10 of 231 patients, 4.3%) than in the F1CDx group (7 of 464 patients, 1.5%) (p = 0.03).","confidence":0.95,"supports":true}
{"relationship_key":"282388:TREATS:C0011634","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":172,"text_span":"Molecular targeted therapy was administered more frequently in the GenMineTOP group (10 of 231 patients, 4.3%) than in the F1CDx group (7 of 464 patients, 1.5%) (p = 0.03).","confidence":0.95,"supports":true}
{"relationship_key":"2058257:TREATS:C1261473","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":172,"text_span":"Molecular targeted therapy was administered more frequently in the GenMineTOP group (10 of 231 patients, 4.3%) than in the F1CDx group (7 of 464 patients, 1.5%) (p = 0.03).","confidence":0.95,"supports":true}
{"relationship_key":"canon-a258d1d85d16:TREATS:C3539878","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":113,"text_span":"BGNps exerted potent, concentration-dependent cytotoxicity in MDA-MB-231 cells, with an IC50 value of 184.3 µg/ml","confidence":0.95,"supports":true}
{"relationship_key":"canon-a258d1d85d16:TREATS:C3539878","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-a258d1d85d16:INDUCES:canon-94676d449f9b","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-a258d1d85d16:INDUCES:canon-925f7f25fbba","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-a258d1d85d16:INDUCES:canon-e4c14214f658","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-a258d1d85d16:INDUCES:canon-de29e881d7d7","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-a258d1d85d16:UPREGULATES:HGNC:11998","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":143,"text_span":"These effects were associated with marked upregulation of p53 and concurrent downregulation of anti-apoptotic Bcl-2 and mitochondrial ND3 genes","confidence":0.95,"supports":true}
{"relationship_key":"canon-a258d1d85d16:DOWNREGULATES:HGNC:990","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":143,"text_span":"These effects were associated with marked upregulation of p53 and concurrent downregulation of anti-apoptotic Bcl-2 and mitochondrial ND3 genes","confidence":0.95,"supports":true}
{"relationship_key":"canon-a258d1d85d16:DOWNREGULATES:HGNC:7458","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":143,"text_span":"These effects were associated with marked upregulation of p53 and concurrent downregulation of anti-apoptotic Bcl-2 and mitochondrial ND3 genes","confidence":0.95,"supports":true}
{"relationship_key":"C3539878:CHARACTERIZED_BY_ABSENCE_OF:HGNC:3467","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":237,"text_span":"Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 expression","confidence":0.95,"supports":true}
{"relationship_key":"C3539878:CHARACTERIZED_BY_ABSENCE_OF:HGNC:8910","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":237,"text_span":"Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 expression","confidence":0.95,"supports":true}
{"relationship_key":"C3539878:CHARACTERIZED_BY_ABSENCE_OF:HGNC:3430","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":237,"text_span":"Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 expression","confidence":0.95,"supports":true}
{"relationship_key":"C3539878:SUBTYPE_OF:C0006142","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":237,"text_span":"Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 expression","confidence":0.95,"supports":true}
{"relationship_key":"canon-de29e881d7d7:LEADS_TO:canon-925f7f25fbba","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-de29e881d7d7:LEADS_TO:canon-e4c14214f658","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-e4c14214f658:LEADS_TO:canon-94676d449f9b","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-57af35b88574:INCREASES_RISK:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":122,"text_span":"The predominant risk factor for PM is asbestos exposure, with approximately 80% of cases linked to prior asbestos contact.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:7371:INDICATES:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":264,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:7371:INDICATES:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":92,"text_span":"SMRP are the only biomarkers for PM approved by the U.S. Food and Drug Administration (FDA).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:17635:ASSOCIATED_WITH:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":130,"text_span":"The PD-L1 protein plays a central role in the antitumor immune response. sPD-L1 concentrations were positively correlated with OS.","confidence":0.9,"supports":true}
{"relationship_key":"canon-c2f58b90e06a:INDICATES:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":176,"text_span":"miRNAs affect tumor growth, invasion and angiogenesis by binding to mRNAs, thereby influencing the expression of oncogenes and oncogenes and the activity of signaling pathways.","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:31586:ASSOCIATED_WITH:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":275,"text_span":"One of the tumorigenic miRNAs associated with PM development is miR-182-5p. miR-182-5p's oncogenic function was first identified in melanoma, where the miRNA promotes tumor migration and invasion by inhibiting the activity of the forkhead box O3 (FOXO3) transcription factor.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:31586:ASSOCIATED_WITH:HGNC:3821","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":275,"text_span":"One of the tumorigenic miRNAs associated with PM development is miR-182-5p. miR-182-5p's oncogenic function was first identified in melanoma, where the miRNA promotes tumor migration and invasion by inhibiting the activity of the forkhead box O3 (FOXO3) transcription factor.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:12363:ASSOCIATED_WITH:canon-e540fad6c703","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":167,"text_span":"Non-synonymous TSC2 mutations occurred in 80% of chimpanzees, versus ~7% in human HCC, suggesting a species-specific oncogenic pathway linked to the scirrhous subtype.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:12363:ASSOCIATED_WITH:canon-e540fad6c703","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":137,"text_span":"TSC2 alterations are present in only 7% of human HCC patients, whereas 80% of chimpanzees with HCC in our study possessed TSC2 mutations.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:12363:INCREASES_RISK:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":167,"text_span":"Non-synonymous TSC2 mutations occurred in 80% of chimpanzees, versus ~7% in human HCC, suggesting a species-specific oncogenic pathway linked to the scirrhous subtype.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:12363:INCREASES_RISK:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":137,"text_span":"TSC2 alterations are present in only 7% of human HCC patients, whereas 80% of chimpanzees with HCC in our study possessed TSC2 mutations.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:12363:REGULATES:canon-13633f7c3ef8","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":195,"text_span":"TSC2 is a tumor suppressor gene that encodes the protein Tuberin complexing with Hamartin, the protein encoded by TSC1, and together they inhibit the mammalian target of rapamycin (mTOR) pathway.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11998:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":76,"text_span":"Additional recurrently mutated genes included ARID1A, FAT1–4, TP53, and FGA.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:11998:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":97,"text_span":"Shared alterations across species involved canonical drivers such as TP53, CTNNB1, FAT4, and TTN.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:11110:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":76,"text_span":"Additional recurrently mutated genes included ARID1A, FAT1–4, TP53, and FGA.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:2514:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":97,"text_span":"Shared alterations across species involved canonical drivers such as TP53, CTNNB1, FAT4, and TTN.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:23109:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":76,"text_span":"Additional recurrently mutated genes included ARID1A, FAT1–4, TP53, and FGA.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:23109:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":97,"text_span":"Shared alterations across species involved canonical drivers such as TP53, CTNNB1, FAT4, and TTN.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:12403:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":97,"text_span":"Shared alterations across species involved canonical drivers such as TP53, CTNNB1, FAT4, and TTN.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:3661:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":76,"text_span":"Additional recurrently mutated genes included ARID1A, FAT1–4, TP53, and FGA.","confidence":0.9,"supports":true}
{"relationship_key":"canon-ec42032f44fc:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":113,"text_span":"Chimpanzee tumors carried significantly higher coding mutation loads (mean 5632 per sample vs. 96–275 in humans).","confidence":0.95,"supports":true}
{"relationship_key":"canon-a1e8b897b179:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":113,"text_span":"Chimpanzee tumors carried significantly higher coding mutation loads (mean 5632 per sample vs. 96–275 in humans).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:ASSOCIATED_WITH:C0597611","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":123,"text_span":"BRD7 has been confirmed to be lowly expressed in nasopharyngeal carcinoma (NPC) tissues and exerts tumour suppressive roles","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:ASSOCIATED_WITH:C0597611","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":160,"text_span":"BRD7 was confirmed to be down-expressed in NPC and acts as a tumour suppressor in NPC by negatively regulating signalling pathways like ERK, Rb/E2F and PI3K/AKT","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:DECREASES:C0027442","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":123,"text_span":"BRD7 has been confirmed to be lowly expressed in nasopharyngeal carcinoma (NPC) tissues and exerts tumour suppressive roles","confidence":0.95,"supports":true}
{"relationship_key":"C1512554:DECREASES:HGNC:1103","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":110,"text_span":"There was hypermethylation modification in BRD7 promoter, which was negatively correlated with BRD7 expression","confidence":0.95,"supports":true}
{"relationship_key":"canon-b328e9825b31:INCREASES:HGNC:1103","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":165,"text_span":"all five sgRNA-guided CRISPR/dCas9 systems could activate BRD7 and inhibit cell proliferation to varying degrees, among which sgRNA2&sgRNA5 were the most significant","confidence":0.95,"supports":true}
{"relationship_key":"canon-b328e9825b31:DECREASES:C0596290","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":165,"text_span":"all five sgRNA-guided CRISPR/dCas9 systems could activate BRD7 and inhibit cell proliferation to varying degrees, among which sgRNA2&sgRNA5 were the most significant","confidence":0.95,"supports":true}
{"relationship_key":"canon-b328e9825b31:DECREASES:C0596290","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":181,"text_span":"both sgRNA2&sgRNA5 could promote the transcriptional activation by reducing its methylation, and inhibit the cell proliferation, migration, invasion and tumour growth in vivo of NPC","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:REGULATES:canon-7a7ef7b45c29","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":160,"text_span":"BRD7 was confirmed to be down-expressed in NPC and acts as a tumour suppressor in NPC by negatively regulating signalling pathways like ERK, Rb/E2F and PI3K/AKT","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:REGULATES:canon-2efeb30e98ab","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":160,"text_span":"BRD7 was confirmed to be down-expressed in NPC and acts as a tumour suppressor in NPC by negatively regulating signalling pathways like ERK, Rb/E2F and PI3K/AKT","confidence":0.95,"supports":true}
{"relationship_key":"canon-b328e9825b31:TREATS:C0027442","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":181,"text_span":"both sgRNA2&sgRNA5 could promote the transcriptional activation by reducing its methylation, and inhibit the cell proliferation, migration, invasion and tumour growth in vivo of NPC","confidence":0.95,"supports":true}
{"relationship_key":"1298331:TREATS:C0006142","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":167,"text_span":"This strategy has driven the development of sophisticated targeted therapies in cancer, such as PARP inhibitors for patients with BRCA1- or BRCA2-mutated breast cancer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1100:ASSOCIATED_WITH:C0006142","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":167,"text_span":"This strategy has driven the development of sophisticated targeted therapies in cancer, such as PARP inhibitors for patients with BRCA1- or BRCA2-mutated breast cancer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1101:ASSOCIATED_WITH:C0006142","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":167,"text_span":"This strategy has driven the development of sophisticated targeted therapies in cancer, such as PARP inhibitors for patients with BRCA1- or BRCA2-mutated breast cancer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:3527:ASSOCIATED_WITH:C0018939","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":256,"text_span":"Among different candidates, we identified the essentiality of EZH2 specifically in hematological cancer cell lines in all iMR models build on TRRUST. Interestingly, this gene has been previously identified as a drug target of different hematological tumors","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:3527:INTERACTS_WITH:HGNC:6204","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":215,"text_span":"the lethality of EZH2 inhibition is mediated by the following gMIS: {EZH2−, JUN−, RELA+}, hypothesizing a higher impact in cellular proliferation when the expression of JUN is down-regulated and RELA is up-regulated","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:3527:INTERACTS_WITH:HGNC:9955","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":215,"text_span":"the lethality of EZH2 inhibition is mediated by the following gMIS: {EZH2−, JUN−, RELA+}, hypothesizing a higher impact in cellular proliferation when the expression of JUN is down-regulated and RELA is up-regulated","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:3071:INTERACTS_WITH:HGNC:4096","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":183,"text_span":"consider the SDL interaction formed by the following two genes: {DUSP4+; GADD45B−}, where the high expression of DUSP4 and the low expression of GADD45B inhibit cellular proliferation","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:1775:INTERACTS_WITH:HGNC:10840","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":186,"text_span":"we also examined the following tumor suppressor gene complex comprising two genes: {CDK5RAP3+; SHC1+}, where the high expression of both genes is required to block cellular proliferation","confidence":0.8,"supports":true}
{"relationship_key":"canon-383f2f24a702:ASSOCIATED_WITH:C0006826","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":197,"text_span":"The manipulation of ferroptosis has become an attractive area of cancer research, as both the promotion and inhibition of this form of cell death have been seen to positively affect cancer outcomes","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:11998:REGULATES:HGNC:11059","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":202,"text_span":"TP53 is the most frequently mutated tumor-suppressor gene and can play an important role in the promotion of ferroptosis in cancer. It downregulates SLC7A11 expression, a key component of the xCT system","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11998:PROMOTES:canon-383f2f24a702","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":202,"text_span":"TP53 is the most frequently mutated tumor-suppressor gene and can play an important role in the promotion of ferroptosis in cancer. It downregulates SLC7A11 expression, a key component of the xCT system","confidence":0.95,"supports":true}
{"relationship_key":"1797886:INHIBITS:HGNC:11059","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":204,"text_span":"Erastin acts through the inhibition of the xCT antiporter composed of both SLC7A11 and SLC3A2. Inhibition of this antiporter leads to decreased intracellular cystine uptake and subsequent depletion of GSH","confidence":0.95,"supports":true}
{"relationship_key":"1797886:INDUCES:canon-383f2f24a702","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":204,"text_span":"Erastin acts through the inhibition of the xCT antiporter composed of both SLC7A11 and SLC3A2. Inhibition of this antiporter leads to decreased intracellular cystine uptake and subsequent depletion of GSH","confidence":0.95,"supports":true}
{"relationship_key":"canon-116802015e6b:INHIBITS:HGNC:4555","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":102,"text_span":"RSL3 is another induction molecule that directly inhibits GPX4 by bypassing the need for GSH depletion","confidence":0.95,"supports":true}
{"relationship_key":"canon-116802015e6b:INDUCES:canon-383f2f24a702","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":102,"text_span":"RSL3 is another induction molecule that directly inhibits GPX4 by bypassing the need for GSH depletion","confidence":0.95,"supports":true}
{"relationship_key":"608804:TREATS:C2239176","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":134,"text_span":"An HCC study has shown that sorafenib enhances ferroptosis through the inhibition of SLC7A11 and subsequent decrease in cystine uptake","confidence":0.9,"supports":true}
{"relationship_key":"608804:INHIBITS:HGNC:11059","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":134,"text_span":"An HCC study has shown that sorafenib enhances ferroptosis through the inhibition of SLC7A11 and subsequent decrease in cystine uptake","confidence":0.9,"supports":true}
{"relationship_key":"canon-40bfab6f8f01:REQUIRED_FOR:canon-383f2f24a702","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":193,"text_span":"Ferroptosis is an iron-dependent form of programmed cell death that is driven by the accumulation of reactive oxygen species (ROS), leading to the formation of membrane-damaging lipid peroxides","confidence":0.95,"supports":true}
{"relationship_key":"canon-e48ccab7179a:CAUSES:canon-18c47ff81482","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":193,"text_span":"Ferroptosis is an iron-dependent form of programmed cell death that is driven by the accumulation of reactive oxygen species (ROS), leading to the formation of membrane-damaging lipid peroxides","confidence":0.95,"supports":true}
{"relationship_key":"canon-18c47ff81482:LEADS_TO:canon-383f2f24a702","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":193,"text_span":"Ferroptosis is an iron-dependent form of programmed cell death that is driven by the accumulation of reactive oxygen species (ROS), leading to the formation of membrane-damaging lipid peroxides","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:3229:INCREASES_EXPRESSION_OF:HGNC:11191","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":95,"text_span":"EGF supplement significantly upregulates both the protein and mRNA expression of the Sox11 gene","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11364:REGULATES:HGNC:11191","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":111,"text_span":"STAT3 bound to the Sox11 gene promoter and transcriptionally upregulated the expression of Sox11 in HNSCC cells","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:PROMOTES:canon-dc2593c6b0a9","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":182,"text_span":"Knockdown of SOX11 significantly downregulated the expression of EMT-related genes, including EMT-TFs, vimentin, fibronectin, and N-cadherin, but significantly upregulated E-cadherin","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:PROMOTES:canon-dc2593c6b0a9","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:12428","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":68,"text_span":"SOX11 bound to the promoter region of the Twist1 gene in HNSCC cells","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:12428","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":82,"text_span":"SOX11 was found to promote HNSCC tumor growth and the expression of TWIST1 in vivo","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:12692","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":182,"text_span":"Knockdown of SOX11 significantly downregulated the expression of EMT-related genes, including EMT-TFs, vimentin, fibronectin, and N-cadherin, but significantly upregulated E-cadherin","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:12692","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:3778","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":182,"text_span":"Knockdown of SOX11 significantly downregulated the expression of EMT-related genes, including EMT-TFs, vimentin, fibronectin, and N-cadherin, but significantly upregulated E-cadherin","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:3778","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:1759","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":182,"text_span":"Knockdown of SOX11 significantly downregulated the expression of EMT-related genes, including EMT-TFs, vimentin, fibronectin, and N-cadherin, but significantly upregulated E-cadherin","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:1759","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:DECREASES_EXPRESSION_OF:HGNC:1748","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":182,"text_span":"Knockdown of SOX11 significantly downregulated the expression of EMT-related genes, including EMT-TFs, vimentin, fibronectin, and N-cadherin, but significantly upregulated E-cadherin","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:DECREASES_EXPRESSION_OF:HGNC:1748","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:ASSOCIATED_WITH:C1168401","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":82,"text_span":"SOX11 was found to promote HNSCC tumor growth and the expression of TWIST1 in vivo","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11393:ASSOCIATED_WITH:C0019204","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":190,"text_span":"AURKA level was significantly increased in both test groups (p < 0.001). At the protein level, AURKA was significantly higher in both cancer groups compared to the control group (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11393:ASSOCIATED_WITH:C0019204","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":190,"text_span":"AURKA level was significantly increased in both test groups (p < 0.001). At the protein level, AURKA was significantly higher in both cancer groups compared to the control group (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11393:PHOSPHORYLATES:HGNC:9077","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":110,"text_span":"AURKA directly phosphorylates the Thr210 residue within the PLK1 kinase domain, initiating mitotic progression","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11393:PHOSPHORYLATES:HGNC:11998","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":198,"text_span":"Overexpression of AURKA has been shown to destabilize p53 through Ser315 phosphorylation, leading to loss of function, centrosome amplification, chromosomal instability, and oncogenic transformation","confidence":0.95,"supports":true}
{"relationship_key":"1298331:SYNERGISTIC_WITH:608406","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":117,"text_span":"experimental studies have demonstrated that MLN8237 exhibits a strong synergistic effect with Sorafenib in HCC models","confidence":0.9,"supports":true}
{"relationship_key":"1298331:TREATS:C0019204","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":117,"text_span":"experimental studies have demonstrated that MLN8237 exhibits a strong synergistic effect with Sorafenib in HCC models","confidence":0.9,"supports":true}
{"relationship_key":"C0019204:SUBTYPE_OF:C0019204","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":190,"text_span":"AURKA level was significantly increased in both test groups (p < 0.001). At the protein level, AURKA was significantly higher in both cancer groups compared to the control group (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"C0019204:SUBTYPE_OF:C0019204","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":190,"text_span":"AURKA level was significantly increased in both test groups (p < 0.001). At the protein level, AURKA was significantly higher in both cancer groups compared to the control group (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11998:INDICATES:C0085390","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":120,"text_span":"When TP53 PVs/LPVs are identified in a comprehensive germline panel, this raises concern for Li–Fraumeni syndrome (LFS).","confidence":0.95,"supports":true}
{"relationship_key":"C0085390:INCREASES_RISK:C0006142","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":212,"text_span":"LFS is a hereditary cancer syndrome that is associated with increased risk for multiple cancers, including, but not limited to, breast cancer, sarcoma, central nervous system tumors, and adrenocortical carcinoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0085390:INCREASES_RISK:C0006142","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":129,"text_span":"The breast cancer risk for women with LFS/germline TP53 LPVs/PVs is 80%–90%, with most breast cancers occurring at a younger age.","confidence":0.95,"supports":true}
{"relationship_key":"C0085390:INCREASES_RISK:C1261473","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":212,"text_span":"LFS is a hereditary cancer syndrome that is associated with increased risk for multiple cancers, including, but not limited to, breast cancer, sarcoma, central nervous system tumors, and adrenocortical carcinoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0085390:INCREASES_RISK:C0006118","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":212,"text_span":"LFS is a hereditary cancer syndrome that is associated with increased risk for multiple cancers, including, but not limited to, breast cancer, sarcoma, central nervous system tumors, and adrenocortical carcinoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0085390:INCREASES_RISK:C0001623","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":212,"text_span":"LFS is a hereditary cancer syndrome that is associated with increased risk for multiple cancers, including, but not limited to, breast cancer, sarcoma, central nervous system tumors, and adrenocortical carcinoma.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11998:ASSOCIATED_WITH:C0206650","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":82,"text_span":"Phyllodes tumors have been associated with germline TP53, BRCA1, and RB1 PVs/LPVs.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1100:ASSOCIATED_WITH:C0206650","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":82,"text_span":"Phyllodes tumors have been associated with germline TP53, BRCA1, and RB1 PVs/LPVs.","confidence":0.95,"supports":true}
{"relationship_key":"C0085390:INCREASES_RISK:C1522449","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":159,"text_span":"It has been demonstrated that patients with LFS who receive radiation therapy have an increased risk of radiation‐related malignancies within irradiated areas.","confidence":0.95,"supports":true}
{"relationship_key":"C0024881:TREATS:C0006142","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":129,"text_span":"The breast cancer risk for women with LFS/germline TP53 LPVs/PVs is 80%–90%, with most breast cancers occurring at a younger age.","confidence":0.95,"supports":true}
{"relationship_key":"canon-f3243a82ae55:TREATS:C0037929","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":248,"text_span":"Following BMSC transplantation, motoneurons extent of shrinkage were reduced and the animals' Basso, Beattie, and Bresnahan (BBB) locomotion scale scores were significantly higher at 21 and 28 days after injury when compared with the injured group.","confidence":0.95,"supports":true}
{"relationship_key":"canon-f3243a82ae55:TREATS:C0037929","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":132,"text_span":"At days 21 and 28 after injury, the hSCI + BMSCs group had significantly higher BBB scores than did the hSCI alone group (p < 0.05).","confidence":0.95,"supports":true}
{"relationship_key":"canon-f3243a82ae55:INCREASES:canon-ba2a56b7e346","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":248,"text_span":"Following BMSC transplantation, motoneurons extent of shrinkage were reduced and the animals' Basso, Beattie, and Bresnahan (BBB) locomotion scale scores were significantly higher at 21 and 28 days after injury when compared with the injured group.","confidence":0.95,"supports":true}
{"relationship_key":"canon-f3243a82ae55:INCREASES:canon-ba2a56b7e346","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":132,"text_span":"At days 21 and 28 after injury, the hSCI + BMSCs group had significantly higher BBB scores than did the hSCI alone group (p < 0.05).","confidence":0.95,"supports":true}
{"relationship_key":"canon-f3243a82ae55:DECREASES:canon-f0de5e05b98b","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":138,"text_span":"BMSC transplantation greatly reduced the density of GFAP staining, suggesting that transplanted BMSCs inhibited scar formation (p < 0.05).","confidence":0.95,"supports":true}
{"relationship_key":"canon-f3243a82ae55:INCREASES:HGNC:2169","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":193,"text_span":"Corresponding elevations in the expression of STAT3 and CNTF mRNA were observed in the hSCI + BMSCs group, and the levels were not significantly different from those observed in the sham group.","confidence":0.95,"supports":true}
{"relationship_key":"canon-f3243a82ae55:INCREASES:HGNC:2169","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":126,"text_span":"The CNTF and STAT3 mRNA levels in the hSCI + BMSC group were markedly upregulated (p < 0.05) compared to the hSCI alone group.","confidence":0.95,"supports":true}
{"relationship_key":"canon-f3243a82ae55:INCREASES:HGNC:11364","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":193,"text_span":"Corresponding elevations in the expression of STAT3 and CNTF mRNA were observed in the hSCI + BMSCs group, and the levels were not significantly different from those observed in the sham group.","confidence":0.95,"supports":true}
{"relationship_key":"canon-f3243a82ae55:INCREASES:HGNC:11364","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":126,"text_span":"The CNTF and STAT3 mRNA levels in the hSCI + BMSC group were markedly upregulated (p < 0.05) compared to the hSCI alone group.","confidence":0.95,"supports":true}
